Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Swanson

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
Brachytherapy|February 6, 2013
Improving prostate brachytherapy quality assurance with MRI-CT fusion-based sector analysis in a phase II prospective trial of men with intermediate-risk prostate cancerAaron P Brown, Thomas J Pugh, David A Swanson, et al.
BJU International|April 3, 2009
Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinomaDanai D Daliani, Nizar M Tannir, Christos N Papandreou, et al.
Urology|July 11, 2009
Urinary side effects and complications after permanent prostate brachytherapy: the MD Anderson Cancer Center experienceJohn F Anderson, David A Swanson, Lawrence B Levy, et al.
The Journal of Urology|February 24, 2009
Prostogram predicted brachytherapy outcomes are not universally accurate: an analysis based on the M. D. Anderson Cancer Center experience with (125)iodine brachytherapySteven J Frank, Lawrence B Levy, Deborah A Kuban, et al.
The Journal of Urology|July 13, 2004
Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experienceArlene O Siefker-Radtke, Colin P Dinney, Neil A Abrahams, et al.
The Journal of Urology|May 29, 2003
Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?Paul Sweeney, Randall Millikan, Machelle Donat, et al.
Brachytherapy|June 8, 2012
Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: implications for prostate brachytherapyThomas J Pugh, Steven J Frank, Mary Achim, et al.
The Journal of Urology|February 14, 2006
The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinomaAshish M Kamat, Jason R Gee, Colin P N Dinney, et al.
Brachytherapy|December 23, 2017
Patient-reported health-related quality of life for men treated with low-dose-rate prostate brachytherapy as monotherapy with 125-iodine, 103-palladium, or 131-cesium: Results of a prospective phase II studyPierre Blanchard, Thomas J Pugh, David A Swanson, et al.
Journal of Contemporary Brachytherapy|January 25, 2013
Long-term tumor control after brachytherapy for base-of-prostate cancerJason M Samuelian, David A Swanson, Rajat J Kudchadker, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Brachytherapy|February 6, 2013
Improving prostate brachytherapy quality assurance with MRI-CT fusion-based sector analysis in a phase II prospective trial of men with intermediate-risk prostate cancerAaron P Brown, Thomas J Pugh, David A Swanson, et al.
BJU International|April 3, 2009
Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinomaDanai D Daliani, Nizar M Tannir, Christos N Papandreou, et al.
Urology|July 11, 2009
Urinary side effects and complications after permanent prostate brachytherapy: the MD Anderson Cancer Center experienceJohn F Anderson, David A Swanson, Lawrence B Levy, et al.
The Journal of Urology|February 24, 2009
Prostogram predicted brachytherapy outcomes are not universally accurate: an analysis based on the M. D. Anderson Cancer Center experience with (125)iodine brachytherapySteven J Frank, Lawrence B Levy, Deborah A Kuban, et al.
The Journal of Urology|July 13, 2004
Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experienceArlene O Siefker-Radtke, Colin P Dinney, Neil A Abrahams, et al.
The Journal of Urology|May 29, 2003
Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?Paul Sweeney, Randall Millikan, Machelle Donat, et al.
Brachytherapy|June 8, 2012
Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: implications for prostate brachytherapyThomas J Pugh, Steven J Frank, Mary Achim, et al.
The Journal of Urology|February 14, 2006
The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinomaAshish M Kamat, Jason R Gee, Colin P N Dinney, et al.
Brachytherapy|December 23, 2017
Patient-reported health-related quality of life for men treated with low-dose-rate prostate brachytherapy as monotherapy with 125-iodine, 103-palladium, or 131-cesium: Results of a prospective phase II studyPierre Blanchard, Thomas J Pugh, David A Swanson, et al.
Journal of Contemporary Brachytherapy|January 25, 2013
Long-term tumor control after brachytherapy for base-of-prostate cancerJason M Samuelian, David A Swanson, Rajat J Kudchadker, et al.
Pageof 7